Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target Raised to $25.00

Amneal Pharmaceuticals (NASDAQ:AMRX) had its price objective upped by research analysts at JPMorgan Chase & Co. from $24.00 to $25.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 25.74% from the company’s previous close.

A number of other equities research analysts have also commented on AMRX. Barclays raised their price target on Amneal Pharmaceuticals from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, September 17th. UBS Group reissued a “buy” rating on shares of Amneal Pharmaceuticals in a research note on Thursday, October 1st. Oppenheimer assumed coverage on shares of Amneal Pharmaceuticals in a report on Wednesday, September 23rd. They set an “outperform” rating and a $27.00 target price on the stock. Zacks Research raised shares of Amneal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, October 26th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a report on Wednesday. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $22.75.

Amneal Pharmaceuticals Trading Down 1.6%

Shares of AMRX stock traded down $0.33 on Wednesday, hitting $19.88. The stock had a trading volume of 2,047,642 shares, compared to its average volume of 2,410,447. The company has a current ratio of 2.20, a quick ratio of 1.44 and a debt-to-equity ratio of 77.65. Amneal Pharmaceuticals has a twelve month low of $11.14 and a twelve month high of $21.68. The company has a fifty day moving average price of $19.22 and a two-hundred day moving average price of $15.82. The firm has a market cap of $6.35 billion, a P/E ratio of 40.47, a PEG ratio of 2.38 and a beta of 1.24.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.23 by $0.03. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%. The business had revenue of $862.68 million for the quarter. As a group, analysts forecast that Amneal Pharmaceuticals will post 0.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, EVP Jason Daly sold 210,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total value of $3,654,000.00. Following the completion of the transaction, the executive vice president directly owned 35,171 shares in the company, valued at $611,975.40. This trade represents a 85.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Nikita Shah sold 146,403 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the transaction, the executive vice president owned 253,390 shares in the company, valued at approximately $4,436,858.90. The trade was a 36.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 413,016 shares of company stock valued at $7,216,567 in the last three months. 17.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Amneal Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of AMRX. Public Employees Retirement System of Ohio bought a new position in Amneal Pharmaceuticals during the 2nd quarter worth $29,000. Fortitude Family Office LLC lifted its position in shares of Amneal Pharmaceuticals by 100.9% during the 3rd quarter. Fortitude Family Office LLC now owns 1,607 shares of the company’s stock valued at $32,000 after acquiring an additional 807 shares during the period. GAMMA Investing LLC grew its holdings in shares of Amneal Pharmaceuticals by 54.9% during the 3rd quarter. GAMMA Investing LLC now owns 1,605 shares of the company’s stock worth $32,000 after purchasing an additional 569 shares in the last quarter. Sterling Capital Management LLC grew its holdings in shares of Amneal Pharmaceuticals by 30.3% during the 3rd quarter. Sterling Capital Management LLC now owns 3,549 shares of the company’s stock worth $71,000 after purchasing an additional 825 shares in the last quarter. Finally, KBC Group NV acquired a new stake in shares of Amneal Pharmaceuticals during the 1st quarter worth $80,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Key Headlines Impacting Amneal Pharmaceuticals

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q3 revenue was approximately $863 million, while adjusted diluted EPS of $0.26 beat analyst expectations. Adjusted EBITDA was $207 million. Amneal Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Amneal raised its 2026 full-year guidance, citing growth in its Affordable Medicines and Specialty businesses. The improved outlook may support expectations for continued growth. AMRX Q3 Earnings & Sales Beat Estimates, FY’26 Guidance Raised
• Negative Sentiment: The company recorded a GAAP net loss of $22 million, or $0.06 per diluted share, and disclosed asset impairment charges. These items may weigh on sentiment despite the adjusted earnings beat. Amneal Announces Asset Impairment Charges

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.